Freya Biosciences is a Copenhagen, Denmark–based transatlantic biotech focused on women’s health and microbial immunotherapies. The company develops therapies that regulate immune and inflammatory responses in the vaginal tract using its DYSCOVERTM platform. Freya has identified Lactobacillus strains capable of engrafting in the vaginal tract to displace a dysbiotic vaginal microbiome and reduce key inflammation biomarkers. Its platform has produced a lead candidate, FB301, aimed at improving pregnancy success in IVF. The company intends to use new funding to develop a microbial immunotherapy for bacterial vaginosis (BV) to address pre-term birth and potentially other maternal and newborn health indications. Freya is led by CEO Colleen Acosta. Freya Biosciences is a clinical-stage, trans‑Atlantic biotech headquartered in Copenhagen and Boston focused on microbial immunotherapies to address reproductive health. Its lead product is an investigational vaginal microbial immunotherapeutic intended to treat infertility in women with dysbiotic vaginal microbiota who are undergoing assisted reproductive technology (ART). The company also operates a multi-omics data science platform that includes deep microbiome sequencing and extensive multiplexed immune biomarker profiling on human clinical samples. Freya plans to use new funding to advance clinical development of its lead candidate and further develop its data science platform. Management cites recent positive topline clinical results as supportive of the program’s potential. The company raised a $38 million Series A to fund these activities, positioning it to expand development and evidence generation in reproductive immunotherapies.

Total raised

$50M

Funding rounds

3

Latest round

Equity

Latest activity

Nov 2024